AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1381788 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine
Number of subjects: 10
Study 1381788 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol
Number of subjects: 10
Study 1381788 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 6094451 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 g cefotaxime before surgery
Number of subjects: 72
Study 6094451 — intervention group
Group type: COMPARATOR
Intervention: 2.0 g cefoxitin pre-operatively and every 8 h for no more than 24 h post-operatively
Number of subjects: 72
Study 31618706 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood pressure (SMBP) intervention
Number of subjects: 158
Study 31618706 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 158
Study 29417920 — intervention group
Group type: COMPARATOR
Intervention: Standard protection
Number of subjects: 30
Study 29417920 — intervention group
Group type: COMPARATOR
Intervention: Personal protective equipment (PPE)
Number of subjects: 30
Study 29417920 — intervention group
Group type: COMPARATOR
Intervention: Portable isolation unit (PIU)
Number of subjects: 30
Study 29417920 — intervention group
Group type: COMPARATOR
Intervention: Airway management difficulty rating (VAS 0-100) in PIU
Number of subjects: 30
Study 27038786 — intervention group
Group type: EXPERIMENTAL
Intervention: i-Sleep (5-session guided online treatment)
Number of subjects: 160
Study 27038786 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual
Number of subjects: 160
Study 27884184 — intervention group
Group type: EXPERIMENTAL
Intervention: Prudent diet
Number of subjects: 190
Study 27884184 — intervention group
Group type: COMPARATOR
Intervention: Western diet
Number of subjects: 190
Study 22743003 — intervention group
Group type: EXPERIMENTAL
Intervention: K-complex density
Number of subjects: 20
Study 22743003 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow wave sleep (SWS) duration
Number of subjects: 20
Study 22743003 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 20
Study 20345617 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous prostaglandin E1 (PGE) 60 microg in 100 mL saline
Number of subjects: 24
Study 20345617 — intervention group
Group type: COMPARATOR
Intervention: Placebo (100 mL saline)
Number of subjects: 24
Study 17910898 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal muscle activation levels (biofeedback from the right external oblique muscle)
Number of subjects: 9
Study 15991504 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (i.v.) ketamine 0.15 mg kg(‐1) before induction and 2 microg kg(‐1) min(‐1) during anaesthesia
Number of subjects: 62
Study 15991504 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered in a similar manner
Number of subjects: 62
Study 12762609 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% Eutectic Mixture of Local Anesthetics (EMLA) cream applied for 3 minutes
Number of subjects: 20
Study 12762609 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% Eutectic Mixture of Local Anesthetics (EMLA) cream applied for 5 minutes
Number of subjects: 20
Study 12762609 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% Eutectic Mixture of Local Anesthetics (EMLA) cream applied for 10 minutes
Number of subjects: 20
Study 12762609 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied for 3, 5, or 10 minutes
Number of subjects: 20
Study 10477166 — intervention group
Group type: COMPARATOR
Intervention: Granisetron 3 mg i.m. daily (plus placebo)
Number of subjects: 532
Study 10477166 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 3 mg i.m. daily plus dexamethasone 8 and 4 mg twice daily
Number of subjects: 532
Study 9097713 — intervention group
Group type: EXPERIMENTAL
Intervention: BrdUrd LI
Number of subjects: 37
Study 9097713 — intervention group
Group type: EXPERIMENTAL
Intervention: AgNOR technique
Number of subjects: 37
Study 9097713 — intervention group
Group type: EXPERIMENTAL
Intervention: S-phase fraction (SPF)
Number of subjects: 37
Study 9097713 — intervention group
Group type: EXPERIMENTAL
Intervention: Aneuploid tumours
Number of subjects: 37
Study 9097713 — intervention group
Group type: EXPERIMENTAL
Intervention: AgNOR counts
Number of subjects: 37
Study 1921674 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-snick food (CB)
Number of subjects: 8
Study 1921674 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose (FRU)
Number of subjects: 8
Study 1921674 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 8
Study 6387892 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalexin (25-50 mg/kg body weight per day for 3 days)
Number of subjects: 43
Study 6387892 — intervention group
Group type: COMPARATOR
Intervention: Nitrofurantoin (3-4 mg/kg/day for 10 days)
Number of subjects: 43
Study 31808408 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy (Group 2) - Two pre-RP physical therapist-guided PFMT sessions, including exercises and electromyographic biofeedback, and verbal and written instructions to continue PFMT until RP, which was then resumed after urethral catheter removal.
Number of subjects: 31
Study 31808408 — intervention group
Group type: COMPARATOR
Intervention: Usual post-RP care (Group 1) - Control group receiving standard care after RP.
Number of subjects: 31
Study 30017370 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led transitions-of-care pilot
Number of subjects: 34
Study 27588816 — intervention group
Group type: EXPERIMENTAL
Intervention: AndoSan™
Number of subjects: 50
Study 24870716 — intervention group
Group type: EXPERIMENTAL
Intervention: Seeing the back during tactile acuity testing
Number of subjects: 0
Study 22174437 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin (40 mg) administered alone on day 4
Number of subjects: 32
Study 22174437 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg) administered with darunavir/ritonavir (600/100 mg) on days 15-18
Number of subjects: 32
Study 22174437 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 variants (SLCO1B1*15 and *17)
Number of subjects: 32
Study 22174437 — intervention group
Group type: COMPARATOR
Intervention: Comparison of SLCO1B1 diplotype groups
Number of subjects: 32
Study 19954944 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (60 min of treadmill walking, estimated 55% VO2 peak)
Number of subjects: 9
Study 19954944 — intervention group
Group type: COMPARATOR
Intervention: No exercise (rest)
Number of subjects: 9
Study 19954944 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 9
Study 18246859 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine (Valdoxan)
Number of subjects: 0
Study 18246859 — intervention group
Group type: COMPARATOR
Intervention: Other antidepressant drugs
Number of subjects: 0
Study 17146693 — intervention group
Group type: EXPERIMENTAL
Intervention: Power Training (PT)
Number of subjects: 20
Study 17146693 — intervention group
Group type: COMPARATOR
Intervention: Traditional Resistance Training (TRT)
Number of subjects: 20
Study 15027055 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT/A (BOTOX 15MU)
Number of subjects: 12
Study 15027055 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT/B (NeuroBloc 1500MU)
Number of subjects: 12
Study 15027055 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT/F (15MU)
Number of subjects: 12
Study 15027055 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT/C (15MU)
Number of subjects: 12
Study 15027055 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (placebo)
Number of subjects: 12
Study 11908406 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.3% hydrogen peroxide whitening strip
Number of subjects: 36
Study 11908406 — intervention group
Group type: COMPARATOR
Intervention: 10% carbamide peroxide tray-based bleaching system
Number of subjects: 36
Study 11908406 — intervention group
Group type: COMPARATOR
Intervention: 15% carbamide peroxide tray-based bleaching system
Number of subjects: 36
Study 11908406 — intervention group
Group type: COMPARATOR
Intervention: 20% carbamide peroxide tray-based bleaching system
Number of subjects: 36
Study 9051281 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive restructuring, interoceptive exposure, and in vivo exposure
Number of subjects: 38
Study 9051281 — intervention group
Group type: COMPARATOR
Intervention: Cognitive restructuring, breathing retraining, and in vivo exposure
Number of subjects: 38
Study 7921798 — intervention group
Group type: EXPERIMENTAL
Intervention: 19% hydrogen peroxide solution
Number of subjects: 23
Study 7921798 — intervention group
Group type: COMPARATOR
Intervention: 35% hydrogen peroxide solution
Number of subjects: 23
Study 3713101 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. immunoglobulin (4 X 100 ml) combined with antibiotics
Number of subjects: 104
Study 3713101 — intervention group
Group type: COMPARATOR
Intervention: antibiotics alone
Number of subjects: 104
Study 30968258 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime 100–150 mg/kg/day
Number of subjects: 37
Study 28523596 — intervention group
Group type: EXPERIMENTAL
Intervention: Vismodegib 150 mg daily
Number of subjects: 31
Study 25857271 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant stanol group (n=46) consuming vegetable-oil spread enriched with plant stanols 3 g/day for 6 months
Number of subjects: 92
Study 25857271 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=46) consuming vegetable-oil spread not enriched with plant stanols
Number of subjects: 92
Study 23975226 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 120 mg
Number of subjects: 2620
Study 23975226 — intervention group
Group type: COMPARATOR
Intervention: Zoledronic acid 4 mg
Number of subjects: 2620
Study 21427402 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir therapy
Number of subjects: 5056
Study 21427402 — intervention group
Group type: COMPARATOR
Intervention: No abacavir therapy
Number of subjects: 5056
Study 19773678 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical excision of the involved lymph nodes
Number of subjects: 100
Study 19773678 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic therapy (clarithromycin and rifabutin)
Number of subjects: 100
Study 17105794 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine ER plus tamsulosin
Number of subjects: 878
Study 17105794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 878
Study 17105794 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin
Number of subjects: 878
Study 17105794 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine ER
Number of subjects: 878
Study 15221494 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacalcidol 1 micro g/day with calcium for 6 months
Number of subjects: 80
Study 15221494 — intervention group
Group type: COMPARATOR
Intervention: Calcium (control group)
Number of subjects: 80
Study 11592566 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone therapy at a dose of 1.5 mg/m2/day
Number of subjects: 46
Study 11592566 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone therapy at a dose of 0.3 mg/m2/day
Number of subjects: 46
Study 11592566 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone therapy (any dose)
Number of subjects: 46
Study 11592566 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone therapy at a dose of >0.3 mg/m2/day
Number of subjects: 46
Study 11592566 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone therapy at a dose of <0.3 mg/m2/day
Number of subjects: 46
Study 10345909 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education intervention for children and parents over 3 years
Number of subjects: 962
Study 7978145 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone 100 mg
Number of subjects: 115
Study 7978145 — intervention group
Group type: COMPARATOR
Intervention: Lignocaine 20 mg
Number of subjects: 115
Study 7978145 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline 4 ml
Number of subjects: 115
Study 2659747 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent cisplatin (CDDP 60 mg/m2 day 1 and VP16 120 mg/m2 day 1‐3 every 3‐4 weeks)
Number of subjects: 55
Study 2659747 — intervention group
Group type: COMPARATOR
Intervention: Weekly cisplatin (CDDP 20 mg/m2 and VP16 120 mg/m2)
Number of subjects: 55
Study 2659747 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 55
Study 31704781 — intervention group
Group type: EXPERIMENTAL
Intervention: 2019 authorship practices evaluation
Number of subjects: 26
Study 31704781 — intervention group
Group type: COMPARATOR
Intervention: Comparison with 2003 data
Number of subjects: 26
Study 30525235 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.025%
Number of subjects: 117
Study 30525235 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 117
Study 30525235 — intervention group
Group type: COMPARATOR
Intervention: Brimonidine 0.025% and Vehicle
Number of subjects: 117
Study 28866621 — intervention group
Group type: EXPERIMENTAL
Intervention: Just-in-Time (JIT) intervention using a portable, bedside computer-based procedural adjunct
Number of subjects: 0
Study 28866621 — intervention group
Group type: COMPARATOR
Intervention: Control group (no JIT intervention)
Number of subjects: 0
Study 25924030 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative sedimentation rate <20 mm/h (normal)
Number of subjects: 363
Study 25924030 — intervention group
Group type: COMPARATOR
Intervention: Preoperative sedimentation rate >20 mm/h (above normal)
Number of subjects: 363
Study 23535740 — intervention group
Group type: EXPERIMENTAL
Intervention: High fiber (HF) diet consisting of oat bran, rye bran, and sugar beet fiber
Number of subjects: 25
Study 23535740 — intervention group
Group type: COMPARATOR
Intervention: Low fiber (LF) diet made of equivalent food products to the HF diet, but without adding fibers
Number of subjects: 25
Study 21765364 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine lipoarabinomannan (LAM) test
Number of subjects: 422
Study 21765364 — intervention group
Group type: COMPARATOR
Intervention: Gold standard (positive bacteriology or histopathology)
Number of subjects: 422
Study 19335346 — intervention group
Group type: EXPERIMENTAL
Intervention: Truview infant EVO2 laryngoscope
Number of subjects: 60
Study 19335346 — intervention group
Group type: COMPARATOR
Intervention: Miller blade number 0
Number of subjects: 60
Study 17326999 — intervention group
Group type: EXPERIMENTAL
Intervention: D-IBS patients
Number of subjects: 26
Study 17326999 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 26
Study 15513250 — intervention group
Group type: EXPERIMENTAL
Intervention: Object-based selection processes
Number of subjects: 0
Study 15513250 — intervention group
Group type: EXPERIMENTAL
Intervention: Space-based selection processes
Number of subjects: 0
Study 15513250 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of space-based and object-based manipulations
Number of subjects: 0
Study 11333840 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Carbohydrate Diet (HC diet)
Number of subjects: 7
Study 11333840 — intervention group
Group type: COMPARATOR
Intervention: High-Fat Diet (HF diet)
Number of subjects: 7
Study 9260010 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg.kg‐1 thiopentone iv, isoflurane/N2O maintenance
Number of subjects: 97
Study 9260010 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg.kg‐1 propofol iv, propofol/N2O maintenance (10‐14 mg.kg‐1.hr‐1)
Number of subjects: 97
Study 9260010 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg.kg‐1 propofol iv, propofol/air/O2 maintenance (10‐14 mg.kg‐1.hr‐1)
Number of subjects: 97
Study 9260010 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone-isoflurane
Number of subjects: 97
Study 8288071 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of diuretic therapy
Number of subjects: 15
Study 3548734 — intervention group
Group type: EXPERIMENTAL
Intervention: fenofibrate 300 mg/day
Number of subjects: 33
Study 3548734 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 33
Study 29625879 — intervention group
Group type: EXPERIMENTAL
Intervention: Tivantinib (120 mg twice daily)
Number of subjects: 340
Study 29625879 — intervention group
Group type: COMPARATOR
Intervention: Placebo (twice daily)
Number of subjects: 340
Study 29625879 — intervention group
Group type: EXPERIMENTAL
Intervention: Tivantinib
Number of subjects: 340
Study 29625879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 340
Study 28662956 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical TXA (tTXA)
Number of subjects: 134
Study 28662956 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic TXA (sTXA)
Number of subjects: 134
Study 28662956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 26586317 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic spinal manipulative therapy (CSMT)
Number of subjects: 90
Study 26586317 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sham manipulation)
Number of subjects: 90
Study 26586317 — intervention group
Group type: COMPARATOR
Intervention: Control (usual non-manual management)
Number of subjects: 90
Study 23007223 — intervention group
Group type: EXPERIMENTAL
Intervention: Silverhawk atherectomy
Number of subjects: 19
Study 23007223 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous transluminal angioplasty (PTA)
Number of subjects: 19
Study 21247887 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month strength-training programme
Number of subjects: 150
Study 18444945 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCB1 2677T allele
Number of subjects: 237
Study 18444945 — intervention group
Group type: EXPERIMENTAL
Intervention: IMPDH2 3757C allele
Number of subjects: 237
Study 18444945 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-10 -592A homozygous
Number of subjects: 237
Study 18444945 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF-alpha G-308A with at least one A allele
Number of subjects: 237
Study 16596905 — intervention group
Group type: EXPERIMENTAL
Intervention: Insemination cycles with abnormal seminal viscosity (group I)
Number of subjects: 37
Study 16596905 — intervention group
Group type: COMPARATOR
Intervention: Insemination cycles with normal semen viscosity (group II)
Number of subjects: 37
Study 12611749 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning bright light
Number of subjects: 92
Study 12611749 — intervention group
Group type: COMPARATOR
Intervention: Morning dim red light
Number of subjects: 92
Study 12611749 — intervention group
Group type: COMPARATOR
Intervention: Evening bright light
Number of subjects: 92
Study 11382894 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH (4x50 microgram, at hourly intervals between 2200 and 0100 h)
Number of subjects: 75
Study 11382894 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched controls)
Number of subjects: 75
Study 11382894 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH treatment
Number of subjects: 75
Study 9149741 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide (ETOP), Ifosfamide (IFOS), and Vincristine (VCR) with hyperfractionated radiation therapy (XRT)
Number of subjects: 68
Study 7957372 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose oral steroids (oral prednisone: 20‐40 mg)
Number of subjects: 70
Study 7957372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 3296841 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone pulse therapy (MPPT) (1000 mg daily for 3 days)
Number of subjects: 6
Study 3296841 — intervention group
Group type: COMPARATOR
Intervention: Standard doses of methylprednisolone (MP) (50 mg daily gradually decreased to zero over 3 weeks)
Number of subjects: 6
Study 30902672 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent energy restriction (2100-2500 kJ [500-600 kcal] diet 2 non-consecutive days/week)
Number of subjects: 137
Study 30902672 — intervention group
Group type: COMPARATOR
Intervention: Continuous energy restriction (5000-6300 kJ [1200-1500 kcal] diet 7 days/week)
Number of subjects: 137
Study 30902672 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 137
Study 28745667 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoflavin (20 ml in 200 ml of 5% glucose solution)
Number of subjects: 60
Study 28745667 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 26521499 — intervention group
Group type: EXPERIMENTAL
Intervention: Debriefing for Meaningful Learning (DML)
Number of subjects: 0
Study 26521499 — intervention group
Group type: COMPARATOR
Intervention: Usual and customary debriefing
Number of subjects: 0
Study 26521499 — intervention group
Group type: COMPARATOR
Intervention: Comparison between DML and usual debriefing
Number of subjects: 0
Study 22903547 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA)
Number of subjects: 2
Study 22903547 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet supplemented with 5% fish oil (high in EPA and DHA)
Number of subjects: 2
Study 21560158 — intervention group
Group type: EXPERIMENTAL
Intervention: fesoterodine 4 mg
Number of subjects: 883
Study 21560158 — intervention group
Group type: EXPERIMENTAL
Intervention: fesoterodine 8 mg
Number of subjects: 883
Study 21560158 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 883
Study 18635306 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified protocol with instruction to 'push as hard as you can'
Number of subjects: 332
Study 18635306 — intervention group
Group type: COMPARATOR
Intervention: MPDS protocol with instruction to 'push down firmly 2in. (5cm)'
Number of subjects: 332
Study 17151163 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based bibliotherapy self-help program with short weekly telephone calls
Number of subjects: 60
Study 17151163 — intervention group
Group type: COMPARATOR
Intervention: Wait-listed control group
Number of subjects: 60
Study 12675461 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional heat-cured acrylic resin dentures
Number of subjects: 17
Study 12675461 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid heat-cured acrylic resin dentures
Number of subjects: 17
Study 12969696 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal E(2) (50 microg)
Number of subjects: 152
Study 12969696 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral E(2) (1 mg)
Number of subjects: 152